BioGPU The cellular biology runtime for AI agents
Enabling AI to run cellular network experiments and close the loop with functional biology to design better, safer drugs.
Already built. Already in use.
Anima has built BioGPU, the cellular biology runtime for AI agents: a foundation model-driven experimental platform developed over more than a decade.
$150M+
BioGPU was developed with over $150 million received through strategic pharmaceutical collaborations with Lilly, Takeda and AbbVie.
See the collaborations →- 25Drug-discovery programs powered
- 150+Cellular systems
- 25Diseases across therapeutic areasSuch as oncology, immunology, neuroscience, fibrosis and gastrointestinal
What AI is missing
AI agents are blind to biology. With BioGPU, they see it.
Structure and chemistry come with decades of public data, and AI has learned them. What a drug does inside a diseased cell has no such dataset: it has to be measured, experiment by experiment. That is the biology that decides efficacy and safety, and it is what BioGPU gives AI.
The platform
BioGPU AI-to-Cell technology stack
One integrated stack: design goes down to the cells, evidence comes back up to the agent.
- AI agentsDesign and orchestrate cellular network experiments.
- Patient-derived cellsWhere the data is produced: the disease itself, in cells from patients.
- Cellular network experimentsRun in the robotic lab, across the whole cellular network.
- Molecular-specific visualizersMake each molecular activity visible inside the network.
- Visual Biology Foundation ModelRecognizes the molecular activities and the network state.
- Cellular Biology TokensCarry the evidence back to the agent.
Applications
Every drug acts on a network. Now AI can design against it.
Design loops today optimize binding and properties, and learn what a drug does to the cell much later, in animal studies and the clinic. BioGPU brings that response into the loop at the design stage, for every molecule AI proposes. The resolved network also informs target, mechanism and safety decisions before the first molecule is made.
Example · antibodies
After binding, a drug's biology begins. BioGPU brings it into the design loop.
Industry standard todayAI designs the antibody and validates binding.
Unique to BioGPUWhat the binding does across the cellular network.
The same loop applies across modalities. All therapeutic workflows →
See the pharma workflow → See available targets → Explore cellular systems →
Experimental loop
Reason. Run. Recognize. Resolve.
Inside BioGPU, AI agents work directly on the cellular network. They reason on what the network shows, generate the next hypothesis and run the next cellular network experiment. Every experiment generates fresh data in patient-derived cells. The loop repeats until the network is resolved.
- 01ReasonThe agent reasons on the network state and generates the next hypothesis.
- 02RunBioGPU runs the experiment in the robotic lab.
- 03RecognizeThe Visual Biology Foundation Model recognizes the molecular activities across the network.
- 04ResolveCellular Biology Tokens return the result to the agent, which chooses the next experiment.
The core technology
A foundation model that knows what cell biology looks like.
Its training data did not exist before Anima produced it, and nobody else produces it.
Anima's Visual Biology Foundation Model has learned the visual signatures of protein interactions, translocation, translation, RNA localization and many more. This is what makes cellular network experiments machine-interpretable at scale, and it is what everything in BioGPU runs on.
Cellular network experiments
Biology works as a network. BioGPU interrogates it as one.
The BioGPU Agent places molecular-specific visualizers, fluorescent probes for the activity of proteins and mRNAs, at strategic points across the cellular network. They run together in one experiment in the robotic lab, so the biology comes back as one connected view, not as fragments from separate assays.
Cellular Biology Tokens
Cell biology, in a form AI can reason on.
Cellular Biology Tokens bring the cellular network state into the agent’s context window, so the agent can reason about functional biology. Each experiment produces thousands of tokens.
Intelligence that compounds
The more it runs, the more of the network it resolves, and the better it learns to see biology.
Every iteration adds Cellular Biology Tokens and resolves more connections in the cellular network, and every experiment teaches the foundation model to recognize more of what it sees.
Patient-derived cells
Real disease biology starts in cells from patients.
Every BioGPU experiment runs in a disease-relevant cellular system, including cells derived from patients, so the network AI works on carries the disease itself. Primary, iPSC-derived and engineered systems widen the range, and new ones can be sourced from biobanks, suppliers and research collaborations, or brought by you.
150+ cellular systems run on BioGPU across 25 diseases.
BioGPU in action
Resolving cellular network biology around targets to let AI agents design safer, better drugs.
Powered by AI agents and BioGPU operating in a continuous loop. Applied across three active disease programs, each available to see in a demo.
Healthy donor
RA patientExperimentally resolving the cellular network biology of pathways and targets in patient-derived synovial fibroblasts.
ResolvedPathways · targets
Book a call to see the case →
Normal bronchial
Lung cancerResolving the cellular network around MYC, to optimize compounds against it.
ResolvedCellular network · compound optimization
Book a call to see the case →
Healthy
ALSResolving the cellular network around SOD1, to find a new way to modulate an undruggable target.
ResolvedCellular network · modulation strategy for an undruggable target
Book a call to see the case →Team
Integrated capabilities across every discipline BioGPU needs.
Cell biology, imaging, chemistry, omics, systems biology, AI, software and drug discovery, integrated in one company. That combination is rare.
Leadership
Yochi Slonim M.Sc., Co-founder & CEO, Board member
Iris Alroy PhD., Co-founder & CSO
Avi Eliassaf Chief Operating Officer
Yossi Oulu M.Sc., Vice President, Software Development
Generoso Ianniciello M.Sc., Chief Business Officer
Give your AI the biology it is missing.
Connect drug design with functional biology, for better, safer drugs. Your own agents can plug straight into BioGPU through its Runtime Skills.
Pharma team? See how your AI connects →
Reason · Run · Recognize · Resolve







